Funder
Ministry of Health of the Czech Republic
Agentura Pro Zdravotnický Výzkum České Republiky
Reference33 articles.
1. Tixagevimab and Cilgavimab (Evusheld) in rituximab-treated antineutrophil cytoplasmic antibody vasculitis patients;Aqeel;Kidney Int. Rep.,2022
2. COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis;Barzegar;Mult. Scler. Relat. Disord.,2022
3. Clinical efficacy and safety of tixagevimab and Cilgavimab (Evusheld) on preventing COVID-19 in patients with ms on b-cell depleters. ACTRIMS forum 2023 - poster presentations;Conte;Mult. Scler. J.,2023
4. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters;Conte;Mult. Scler. Relat. Disord.,2022
5. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment;Delgado;J. Neurol.,2023